The first systems for continuous glucose monitoring (CGM) became available over 15 years ago. Many then believed CGM would revolutionize the use of intensive insulin therapy in diabetes; however, progress toward that vision has been gradual. Although increasing, the proportion of individuals using CGM rather than conventional systems for self-monitoring of blood glucose on a daily basis is still low in most parts of the world. Barriers to uptake include cost, measurement reliability (particularly with earlier-generation systems), human factors issues, lack of a standardized format for displaying results, and uncertainty on how best to use CGM data to make therapeutic decisions. This Scientific Statement makes recommendations for systemic improvements in clinical use and regulatory (pre- and postmarketing) handling of CGM devices. The aim is to improve safety and efficacy in order to support the advancement of the technology in achieving its potential to improve quality of life and health outcomes for more people with diabetes.

中文翻译：

---

提高CGM系统的临床价值和实用性：问题和建议

15年前，出现了第一批连续葡萄糖监测（CGM）系统。当时，许多人认为CGM将彻底改变糖尿病患者中强化胰岛素治疗的应用。但是，朝着这个目标迈进的步伐是逐步的。尽管使用CGM而非常规系统进行日常自我血糖监测的个人比例在世界大多数地区仍然很低。吸收的障碍包括成本，测量可靠性（尤其是在早期系统中），人为因素问题，缺乏显示结果的标准化格式以及不确定如何最好地使用CGM数据做出治疗决策的不确定性。该《科学声明》为系统改进CGM设备的临床使用和法规（上市前和上市后）处理提出了建议。